Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes

NCT03684096 | Completed

• 1 other identifier: EC/2017/1261
• Study Type: interventional
• Target: 69
• Locations: 1 country
• Sites: 1

Brief Summary

Many postmenopausal women have vasomotor symptoms during adjuvant hormonal treatment for breast cancer. PCC-100 is a pollen extract used for alleviation of postmenopausal symptoms. In a randomised, double blinded study pollen extract PCC-100 will be used to treat vasomotor complaints in postmenopausal women under adjuvant hormonal treatment and also in menopausal women without a history of breast cancer.

Conditions

Breast Cancer; Hot Flashes; Postmenopausal Symptoms

Outcome Measures

Primary Outcomes (1)

• Daily frequency of hot flashes

  Daily frequency of hot flashes as mentioned in the daily diary the subjects need to complete during 12 weeks. The patient indicate in the diary the number, intensity (mild, moderate, severe) of hotflashes every day

  12 weeks

Secondary Outcomes (3)

• Menopause symptoms

  6-8 weeks after randomisation and 12 weeks after randomisation

• Menopause symptoms

  6-8 weeks after randomisation and 12 weeks after randomisation

• Influence of hot flashes on daily life

  6-8 weeks after randomisation and 12 weeks after randomisation

Study Arms (2)

non-estrogenic pollen extract PCC-100

ACTIVE COMPARATOR

After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.

Dietary Supplement: non-estrogenic pollen extract PCC-100

placebo

PLACEBO COMPARATOR

After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.

Other: placebo

Interventions

non-estrogenic pollen extract PCC-100 DIETARY_SUPPLEMENT

non-estrogenic pollen extract PCC-100

non-estrogenic pollen extract PCC-100

placebo OTHER

placebo -non-estrogenic pollen extract PCC-100

placebo

Eligibility Criteria

• Age: 50 Years - 65 Years
• Gender Eligibility Details: only women will be recruited
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Postmenopausal women, between 50 and 65 years old (extremes included) at the time of signing the informed consent form;
• spontaneous amenorrhea for at least 6 consecutive months in combination with a hormonal diagnosis of being postmenopausal (FSH \> 40 mU/ml and E2 \< 20 pg/ml. In subjects using Tamoxifen, only E2 needs to be determined) or spontaneous amenorrhea for at least 12 consecutive months or having had a bilateral oophorectomy at least 6 weeks prior to screening (with or without hysterectomy);
• a history of breast cancer, whatever the received treatment, and currently taking aromatase inhibitors or Tamoxifen since at least 4 weeks. This criterion is not applicable to the 100 subjects entering the study without a history of breast cancer;
• a minimum of 49 moderate to severe hot flushes or night sweats during 7 consecutive 24-h periods;
• a body mass index \[BMI\] between 18.0 and 35.0 kg/m2, inclusive;
• proven normal glycaemia and normal thyroid function as evidenced in a recent serum analysis (in the last year) performed by the General Practitioner or gynaecologist;
• The subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.

You may not qualify if:

• Recently, an abnormal cervical Pap smear that requires surgery within 6 months;
• acute or chronic thromboembolic disease, liver disease and/or renal impairment;
• uncontrolled diabetes mellitus;
• uncontrolled hypertension;
• uncontrolled thyroid disorders;
• the subject has a history of a major depression or post-traumatic stress disorder \[PTSD\] within 2 years of screening. Women taking antidepressants can be included after a wash out period of 6 weeks;
• use of (non-)hormonal treatments to reduce hot flushes, unless a wash-out period is respected;
• a history or presence of allergy or intolerance to the investigational product or any component of the investigational product or drugs in this class. Or history of drug or other allergy that, in the opinion of the investigator contraindicates subject participation;
• a history of alcohol or substance abuse or dependence in the 12 months before screening as determined by the investigator;
• judged by the investigator to be unsuitable for any reason.

Sponsors & Collaborators

• University Hospital, Ghent: lead

Study Sites (1)

Ghent University Hospital

Ghent, East Flanders, 9000, Belgium

Location

MeSH Terms

Conditions

Breast Neoplasms; Hot Flashes

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2018
• First Posted: September 25, 2018
• Study Start: October 15, 2018
• Primary Completion: January 31, 2023
• Study Completion: January 31, 2023
• Last Updated: February 15, 2024

Record last verified: 2024-02

Locations

BE (1)